5 results match your criteria: "Orlando Health Heart and Vascular Institute[Affiliation]"
Int J Cardiol
December 2024
Division of Cardiology, Cleveland Clinic's Heart, Vascular & Thoracic Institute (HVTI), Cleveland Clinic Florida, Weston, FL, United States.
Background: There is a paucity of data regarding the impact of cardiac conduction disease (CD) on clinical outcomes in patients with cardiac amyloidosis (CA).
Methods: The National Inpatient Sample (NIS) was queried to identify all CA admissions and those with CD using ICD-10 codes from 2016 to 2019. We explored baseline characteristics and used multivariate logistic regression to assess the association between CD and several clinical outcomes during index admission; a p-value of <0.
J Cardiovasc Electrophysiol
August 2024
Department of Cardiology and Electrophysiology, Orlando Health Heart and Vascular Institute, Orlando, Florida, USA.
Introduction: A hybrid convergent approach (endocardial and epicardial ablation) demonstrated superior effectiveness in a recent randomized study for long-standing persistent atrial fibrillation (LSPAF). Yet, there is a lack of real-world, long-term evidence as to which patients are best candidates for a hybrid convergent approach compared to standard endocardial cryoballoon pulmonary vein isolation (CB PVI).
Methods And Results: This single-center, retrospective analysis spanning from 2010 to 2015 compared two distinctly different atrial fibrillation (AF) cohorts; one treated with stand-alone cryoablation and one treated with a hybrid convergent approach.
Am J Cardiovasc Drugs
May 2024
Department of Internal Medicine, University of Texas Southwestern Medical Center, Texas, Dallas, USA.
Aim: The efficacy and safety of bivalirudin when used concurrently with glycoprotein IIb/IIIa inhibitors (GPI) is uncertain. In this systematic review and meta-analysis, we aimed to evaluate the efficacy and safety of bivalirudin versus heparin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) and to explore the impact of differential use (greater and balanced) of GPI.
Methods: Online databases were queried from inception to March 2023 to identify eight randomized controlled trials (n = 22,483) for inclusion.
Cureus
September 2023
Nephrology, Orlando Veterans Affairs Healthcare System, Orlando, USA.
Direct oral anticoagulants (DOACs) have shifted the landscape of anticoagulation over the past decade, becoming a frequently used pharmaceutical agent. The increased use of DOACs for long-term anticoagulation has led to a rise in reported anticoagulant-related adverse reactions, such as anticoagulant-related nephropathy (ARN). The occurrence of ARN is well reported with warfarin; however, there are few cases of ARN reported with DOAC use.
View Article and Find Full Text PDFSurg Clin North Am
June 2022
Orlando Health Heart and Vascular Institute, 1222 South Orange Avenue, Orlando, FL 32806, USA. Electronic address:
This article focuses on the guideline-directed evaluation and management of cardiac dysrhythmias, particularly as they are important to the practice of a noncardiac surgeon. The focus is on atrial fibrillation (AF) as the most common arrhythmia encountered by surgeons. The authors discuss the importance of AF as a risk factor for perioperative morbidity and mortality.
View Article and Find Full Text PDF